We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Meets Today to Discuss ‘Demonstrated Substantial Toxicity’ of PI3K Inhibitors
FDA Advisory Panel Meets Today to Discuss ‘Demonstrated Substantial Toxicity’ of PI3K Inhibitors
The FDA’s Oncologic Drugs Advisory Committee is meeting today and tomorrow to discuss the now controversial phosphatidylinositol 3-kinase (PI3K) inhibitor class of drugs in blood cancers, but based on the agency’s briefing document, the fate of the class, which may be decided at this two-day meeting, seems in doubt.